



February 08, 2011

The Secretary
Bangalore Stock Exchange Ltd.
Stock Exchange Tower
51, 1st Cross, J C Road
Bangalore 560 027

Ref: Scrip Code - Bgse: ASTRAZEN /BSE: 506820 / NSE: ASTRAZEN EQ

Dear Sir,

**Sub: Announcement of un-audited financial results of the Company for the quarter
and twelve months ended December 31, 2010**

Pursuant to Clause 41 of the Listing Agreement, we submit herewith the un-audited financial results of the Company for the quarter and twelve months ended December 31, 2010, duly approved by the Board of Directors of the Company at its meeting held on February 08, 2011.

For your information and record, please.

Thanking you,

Yours faithfully,
for **AstraZeneca Pharma India Limited**


N R Srinivasan
VP – Legal & Company Secretary

Encl: as above

Cc: **Bombay Stock Exchange Limited**
Corporate Relationship Dept., 1st Floor,
P J Towers, Dalal Street, Fort, Mumbai 400 001

National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor, Plot No.C/1,
G Block, Bandra-Kurla Complex, Bandra (E), Mumbai 400 051

National Securities Depository Ltd.
Trade World, 4th Floor, Kamala Mill Compound,
Senapati Bapat Marg, Lower Parel, Mumbai 400 013

Central Depository Services (India) Ltd.
16th Floor, P J Towers, Dalal Street, Fort, Mumbai 400 001


**FINANCIAL RESULTS FOR THE
QUARTER AND TWELVE MONTHS ENDED 31 DECEMBER 2010**

Rs in lakhs (except for number of shares)					
Sl No.	Particulars	3 months ended 31.12.2010 (Unaudited)	3 months ended 31.12.2009 (Unaudited)	Year to date figures for current period ended 31.12.2010 (Unaudited)	Previous accounting year ended 31.12.2009 (Audited)
1	(a) Net sales (net of excise duty)	12,845.04	11,484.89	45,105.73	38,552.12
	(b) Other operating income:				
	- Service income	407.25	139.08	1,629.09	1,111.21
2	Expenditure				
	(a) (Increase)/ decrease in stock-in-trade and work-in-progress	(838.16)	(67.71)	(1,259.17)	12.76
	(b) Consumption of raw materials and packing materials	1,602.63	1,331.35	5,963.96	4,575.41
	(c) Purchase of traded goods	3,175.12	2,219.64	9,262.29	7,507.77
	(d) Employees cost	2,542.19	1,828.59	11,220.15	8,282.94
	(e) Depreciation	185.37	156.38	705.65	607.67
	(f) Other expenditure	2,458.99	2,920.18	12,855.72	10,398.26
	(g) Total	9,126.14	8,388.43	38,748.60	31,384.81
3	Profit from operations before other income, interest & exceptional items (1-2)	4,126.15	3,235.54	7,986.22	8,278.52
4	Other income	153.32	116.36	408.35	574.40
5	Profit before interest & exceptional items (3+4)	4,279.47	3,351.90	8,394.57	8,852.92
6	Interest	-	-	-	13.70
7	Profit after interest but before exceptional items (5-6)	4,279.47	3,351.90	8,394.57	8,839.22
8	Exceptional items	-	-	-	-
9	Profit from ordinary activities before tax (7+8)	4,279.47	3,351.90	8,394.57	8,839.22
10	Tax expense	1,447.31	1,143.29	2,816.99	3,077.49
11	Net profit from ordinary activities after tax (9-10)	2,832.16	2,208.61	5,577.58	5,761.73
12	Extraordinary Item	-	-	-	-
13	Net profit for the period (11-12)	2,832.16	2,208.61	5,577.58	5,761.73
14	Paid-up equity share capital (Face value of Rs 2 per equity share)	500.00	500.00	500.00	500.00
15	Reserves excluding revaluation reserves as per the balance sheet of previous accounting year				13,951.82
16	Basic and diluted earnings (Rs) per share (not annualised)	11.33	8.83	22.31	23.05
17	Public shareholding				
	- Number of shares	2,500,050	2,500,050	2,500,050	2,500,050
	- Percentage of shareholding	10.0002%	10.0002%	10.0002%	10.0002%
18	Promoters and promoter group shareholding				
	a) Pledged/Encumbered				
	- Number of shares	-	-	-	-
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the Company)	-	-	-	-
	b) Non-encumbered				
	- Number of shares	22,499,950	22,499,950	22,499,950	22,499,950
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%
	- Percentage of shares (as a % of the total share capital of the Company)	89.9998%	89.9998%	89.9998%	89.9998%

Notes :

- The above statement of financial results was reviewed by the Audit Committee and having been recommended for approval, was approved by the Board of Directors of the Company at their meeting held on 08 February 2011.
- Status of investor complaints : a) Pending as on 1 October 2010 - NIL b) Received during the quarter - 4 c) Disposed off during the quarter - 4 d) Pending as on 31 December 2010 - NIL
- The board of directors at their meeting held on 23 February 2010 have approved the change in the Company's statutory accounting year from 'January-December' to 'April- March'. Accordingly, the financial accounts and annual report for the year ending 31 March 2011 shall be for a period of 15 months, i.e. from 1 January 2010 to 31 March 2011.
- 'Employee cost' and 'other expenditure' include reversal of accrual of bonus and IT outsourcing charges of Rs 285 lakhs and Rs 170.7 lakhs respectively, provided for on an estimated basis in the earlier quarters.
- The Company's sole reportable business segment is - 'Healthcare'. The other segments are not material and are hence disclosed as 'Others', Which comprises service income pertaining to clinical trials and co-promotion activities.
- Previous period figures have been regrouped/ reclassified, wherever necessary to conform to the current period's presentation.

By Order of the Board of Directors
For AstraZeneca Pharma India Limited



Anandh Balasundaram
Managing Director

Place: Bangalore
Dated: 08 February 2011

ASTRAZENECA PHARMA INDIA LIMITED
Regd. Office : 'Avishkar' Off Bellary Road, Hebbal, Bangalore 560 024

Segment wise revenue, results and capital employed

Sl No.	Particulars	3 months ended 31.12.2010 (Unaudited)	Corresponding 3 months ended in the previous year 31.12.2009 (Unaudited)	12 months ended 31.12.2010 (Unaudited)	Rs. in lakhs Previous Accounting year ended 31.12.2009 (Audited)
1	Segment Revenue				
	(a) Healthcare	12,850.94	11,488.61	45,128.21	38,583.37
	(b) Others	407.25	139.08	1,629.09	1,111.21
	Total	13,258.19	11,627.69	46,757.30	39,694.58
	Less: Inter-segment Revenue	-	-	-	-
	Net Income From Operations	13,258.19	11,627.69	46,757.30	39,694.58
2	Segment Results				
	Profit before Tax and interest				
	(a) Healthcare	4,077.58	3,233.40	7,847.06	8,286.13
	(b) Others	54.47	5.87	161.64	23.65
	Total	4,132.05	3,239.27	8,008.70	8,309.78
	Add: Other Income	147.42	112.63	385.87	543.14
	Less: Interest	-	-	-	13.70
	Total Profit Before Tax	4,279.47	3,351.90	8,394.57	8,839.22
3	Capital Employed				
	(a) Healthcare	10,499.73	11,595.38	10,499.73	11,595.38
	(b) Others	24.65	(378.11)	24.65	(378.11)
	(c) Unallocated	9,514.67	3,234.55	9,514.67	3,234.55
	Total	20,039.05	14,451.82	20,039.05	14,451.82

Note: Certain assets and liabilities of the Healthcare segment are interchangeably used for other segments for limited purposes. Identification of such assets and liabilities is not feasible. Hence, such assets have not been allocated to any segment.

Swati